Some potential type I c-Met inhibitors, such as 2-aminopyridine derivatives have an important nitrogen heterocyclic structure skeleton with a wide range of biological activities and excellent activities against tumors, which makes it a potential c-Met RTK inhibitors for cancer therapy [16]. The gene discussed is MET; the disease is cancer.